On July 31, Moderna, Inc. rose 5.03% in regular trading, trading at $57.155/share, with turnover of $142 million. The rally came as the company was set to release its Q2 earnings pre-market the same day, combined with a series of analyst price target upgrades and a key pipeline milestone.

On the news front, Goldman Sachs raised its target price on Moderna from $49 to $67 on July 20, maintaining a Neutral rating. Jefferies lifted its target to $60 from $53 on July 13, also maintaining Hold. Piper Sandler previously raised its target to $77 from $69 while maintaining an Overweight rating. The consensus mean target stands at approximately $52.16.

Additionally, the company's seasonal flu vaccine candidate mRNA-1010 received unanimous support (9-0) from the FDA's Vaccines and Related Biological Products Advisory Committee, with a final regulatory decision expected by August 5. Moderna also initiated a Phase 1 trial for its investigational tumor-targeted cancer antigen therapy in solid tumors on July 16, signaling continued pipeline diversification beyond COVID-19 vaccines.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)